Unusual Fusion Proteins of HIV-1 by Simon Langer & Daniel Sauter
REVIEW
published: 09 January 2017
doi: 10.3389/fmicb.2016.02152
Frontiers in Microbiology | www.frontiersin.org 1 January 2017 | Volume 7 | Article 2152
Edited by:
Akio Adachi,
Tokushima University, Japan
Reviewed by:
Kei Sato,
Kyoto University, Japan
Michael M. Thomson,
Instituto de Salud Carlos III, Spain
*Correspondence:
Daniel Sauter
daniel.sauter@uni-ulm.de
Specialty section:
This article was submitted to
Virology,
a section of the journal
Frontiers in Microbiology
Received: 28 October 2016
Accepted: 20 December 2016
Published: 09 January 2017
Citation:
Langer S and Sauter D (2017)
Unusual Fusion Proteins of HIV-1.
Front. Microbiol. 7:2152.
doi: 10.3389/fmicb.2016.02152
Unusual Fusion Proteins of HIV-1
Simon Langer and Daniel Sauter *
Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany
Despite its small genome size, the Human Immunodeficiency Virus 1 (HIV-1) is one of
the most successful pathogens and has infected more than 70 million people worldwide
within the last decades. In total, HIV-1 expresses 16 canonical proteins from only nine
genes within its 10 kb genome. Expression of the structural genes gag, pol, and env,
the regulatory genes rev and tat and the accessory genes vpu, nef, vpr, and vif enables
assembly of the viral particle, regulates viral gene transcription, and equips the virus to
evade or counteract host immune responses. In addition to the canonically expressed
proteins, a growing number of publications describe the existence of non-canonical
fusion proteins in HIV-1 infected cells. Most of them are encoded by the tat-env-rev
locus. While the majority of these fusion proteins (e.g., TNV/p28tev, p186Drev, Tat1-Rev2,
Tat∧8c, p17tev, or Ref) are the result of alternative splicing events, Tat-T/Vpt is produced
upon programmed ribosomal frameshifting, and a Rev1-Vpu fusion protein is expressed
due to a nucleotide polymorphism that is unique to certain HIV-1 clade A and C strains. A
better understanding of the expression and activity of these non-canonical viral proteins
will help to dissect their potential role in viral replication and reveal how HIV-1 optimized
the coding potential of its genes. The goal of this review is to provide an overview of
previously described HIV-1 fusion proteins and to summarize our current knowledge of
their expression patterns and putative functions.
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INTRODUCTION
The genome of the Human Immunodeficiency Virus type 1 (HIV-1), the major causative
agent of the current AIDS pandemic, is relatively small, comprising <10,000 bases in total.
Arranged in three different reading frames, it contains only nine canonical genes (Figure 1).
Nevertheless, the virus replicates and spreads efficiently in its human host, which expresses
about 2500 times more protein-coding genes from a three billion base pair genome. How
does a retrovirus with its limited genome size manage to keep pace in this David vs. Goliath
struggle? How can such a tiny genome encode all the tools that are required for efficient
replication and immune evasion in such a hostile environment? One major advantage of
HIV-1 and related retroviruses compared to their host species is certainly their high mutation
rate that allows them to quickly adapt to an ever-changing environment. Furthermore, viral
proteins are often multifunctional and exert a multitude of immune evasion activities. The
paragon of such a multitasking or moonlighting protein is HIV-1 Nef, which has been described
to downmodulate a variety of surface receptors including CD4, MHC class I, CD28, and
CXCR4, counteracts the host restriction factors SERINC3/5, and upregulates the invariant
chain/CD74 to suppress antigen presentation (Pereira and daSilva, 2016). Finally, viral genomes
are often very compact, containing overlapping genes that encode for bi- and multi-cistronic
mRNAs. As a result, viruses frequently utilize non-canonical translation mechanisms such
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as internal ribosomal entry, leaky scanning, ribosomal
frameshifting, shunting, or reinitiation (Firth and Brierley,
2012). Another important mechanism increasing the coding
capacity of viral genomes is alternative splicing. HIV-1 and
related lentiviruses contain dozens of splice donor and acceptor
sites that allow the generation of more than 100 different
mRNA species (Ocwieja et al., 2012; Figure 1). Generation and
translation of these mRNAs are tightly regulated throughout
the viral replication cycle and enable the coordinated synthesis
of structural, regulatory and accessory proteins in an optimized
ratio. For example, expression of the HIV-1 regulatory proteins
FIGURE 1 | Genome and major mRNA transcripts of HIV-1. The HIV-1 genome comprises nine canonical genes that are arranged in three different reading
frames. These genes encode for structural/enzymatic (orange), regulatory (green), and accessory (blue) proteins and are flanked by two long terminal repeats (LTR).
The viral mRNA is spliced into more than 100 different mono- or multi-cistronic mRNA transcripts (Ocwieja et al., 2012), encoding different viral proteins. Splice donor
(D) and acceptor (A) sites are indicted by dotted and dashed vertical lines, respectively.
Tat and Rev requires the joining of two exons (tat1/2 or
rev1/2) via splicing at donor D4 and acceptor A7, whereas all
four accessory proteins (Vif, Vpr, Vpu, and Nef) are encoded
by mono-exonic genes. Notably, vpu overlaps with the viral
envelope (env) gene and both are expressed from bicistronic
mRNA species (Figure 1). Translation of downstream env is
enabled by a weak Kozak sequence of vpu (leaky scanning)
and/or ribosomal shunting mechanisms that allow to bypass
upstream AUG codons (Anderson et al., 2007). While expression
of Env as well as all accessory and regulatory proteins requires
splicing, Gag and Pol are encoded by the 5′ half of the viral
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genome and expressed by unspliced viral mRNA. Gag can
either be expressed alone or, upon ribosomal frameshifting,
as a Gag-Pol poly-protein. The three precursor proteins Gag,
Gag-Pol, and Env are proteolytically processed into mature
proteins: Gag is cleaved by the viral protease into matrix, capsid,
nucleocapsid, and the p6 protein. Similarly, the viral protease
generates the mature viral enzymes reverse transcriptase (p51
and p66), protease and integrase from the Pol precursor protein.
Finally, the Envelope protein is cleaved by the cellular protease
furin into its mature subunits gp120 and gp41.
Considering the multitude of modulatory processes
underlying the expression of viral proteins, it is not surprising
that several studies have reported the expression of non-
canonical fusion proteins by HIV-1. While the majority of these
fusion proteins are the result of alternative splicing events joining
regular or cryptic open reading frames, two of them are expressed
only upon ribosomal frameshifting or gene rearrangements,
respectively. The aim of this review article is to provide an
overview of previously described fusion proteins of HIV-1. We
will summarize our current knowledge on their expression and
generation by different HIV-1 strains, discuss possible roles
during the retroviral life cycle and critically review a potential
relevance for viral replication.
HIV-1 FUSION PROTEINS GENERATED BY
ALTERNATIVE SPLICING
TNV/p28tev
In addition to the canonical splice sites, several studies have
reported the presence of alternative or cryptic splice sites in
different clades of HIV-1 group M (Purcell and Martin, 1993;
Ocwieja et al., 2012; Vega et al., 2016). While some of these
sites are conserved among diverse HIV-1 isolates and seem to
be used regularly, others have only been identified in single
clones of HIV-1 and/or become only active upon mutation of
canonical splice sites. Two well-described examples for cryptic
sites are splice acceptor 6 (A6) and donor 5 (D5), which have
been identified in the genomes of HXB2 and closely related
subtype B strains (Figure 2). Utilization of these sites results in
the generation of a small exon (116 bases) derived from the env
open reading frame (ORF). cDNA analyses revealed that this
exon (designated 6D) may be fused to tat1 and rev2 encoding
exons via splice donor 4 (D4) and acceptor 7 (A7), respectively
(Feinberg et al., 1986; Wright et al., 1986; Benko et al., 1990;
Salfeld et al., 1990; Schwartz et al., 1990a).
Two groups demonstrated that the respective mRNA can be
translated into an unusual tripartite fusion protein comprising
Tat1, 38 amino acids of Env including its V1 loop, and Rev2
(Benko et al., 1990; Salfeld et al., 1990). Salfeld and colleagues
found that this protein migrates at an apparent size of 26 kDa and
was probably identical to the Tat-related protein p26 described
in earlier studies (Feinberg et al., 1986; Wright et al., 1986).
In reference to its parental proteins Tat, Env, and Rev, the
fusion protein was named TNV (Salfeld et al., 1990). The group
of Barbara Felber identified the same protein independently
and termed it p28tev as it migrated slightly slower in their
experiments (Benko et al., 1990). Both studies analyzed the
closely related HIV-1 M clade B HXB2 and/or HXB3 clones.
While Salfeld et al. analyzed the expression of the fusion
protein only in transfected COS-7 cells, Benko and colleagues
demonstrated that TNV/p28tev is also expressed in various
human T cell lines infected with HIV-1 HXB2 (Table 1). In
agreement with the finding that the N-terminus of Tat, encoded
by tat1, is sufficient to transactivate viral transcription (Sodroski
et al., 1985; Cullen, 1990; Vives et al., 1994), TNV/p28tev also
enhances LTR-mediated gene expression and may thus represent
a bona fide regulatory protein. Reporter assays revealed that the
transactivating activity of TNV/p28tev is only about 30% lower
than that of its parental Tat protein (Benko et al., 1990; Salfeld
et al., 1990). In contrast, the fusion protein exerts no (Salfeld et al.,
1990) or only weak (Benko et al., 1990) Rev activity. Due to its
chimeric structure, TNV/p28tev possesses two stretches of basic
amino acids in its Tat1 and Rev2 domains that mediate nucleolar
localization (Benko et al., 1990). The nuclear localization and
absence of a signal peptide probably also prevents glycosylation
despite the presence of four N-linked glycosylation sites in
the Env-derived fragment (Salfeld et al., 1990). Radiolabeling
revealed that TNV/p28tev is weakly phosphorylated, probably at
two phosphate acceptors near its C-terminus (Benko et al., 1990).
This finding is in agreement with the observation that the fusion
protein migrates as a doublet of closely spaced bands in SDS gels
(Göttlinger et al., 1992).
To investigate the importance of TNV/p28tev for viral
replication, Göttlinger and colleagues mutated the A6 and D5
splice sites in env without altering its primary amino acid
sequences. Experiments in Jurkat T cells and PBMCs revealed
that the A6 mutant of HIV-1 HXBc2 replicated as efficiently
as the respective wild type control (Göttlinger et al., 1992).
These findings demonstrate that expression of TNV/p28tev has
no significant effect on viral replication, at least in vitro.
Interestingly, the D5 mutant was replication-defective. However,
this phenotype could be ascribed to the utilization of another
cryptic splice donor that resulted in detrimental intron removal
and possibly reduced Tat and Rev expression levels (Göttlinger
et al., 1992). These results are in agreement with the observation
that most HIV-1 strains lack the cryptic splice sites generating
exon 6D (Göttlinger et al., 1992). In fact, mutations that increase
the amount of TNV/p28tev encoding mRNAs may be detrimental
for viral replication as the expression of functional Rev is reduced
(Göttlinger et al., 1992; Wentz et al., 1997).
Tat1-Rev2 (p21, p24) and Rev1-Tat2
Chimeras
Besides the TNV/p28tev fusion protein, Salfeld and colleagues
observed the expression of two additional proteins (p21, p24)
that are detected by both Rev- and Tat-specific antisera (Salfeld
et al., 1990). They hypothesized that at least one of these two
proteins may represent an alternative Tat-Rev fusion product
that is expressed if tat1 is fused in frame to rev2, without
any additional env sequences. Notably, comprehensive analyses
of mRNA species in HIV-1 infected cells identified several
neighboring splice acceptor sites at the 5′ end of rev2/tat2 that
introduce a frameshift andmay result in the expression of various
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FIGURE 2 | HIV-1 fusion proteins generated by alternative splicing. Several HIV-1 strains encode cryptic (red) and/or alternative splice sites. Splicing at these
sites may result in the generation of mRNA species expressing unusual fusion proteins. For example, TNV, Tat1-Rev2, Tat1-Env, Rev1-Env, p186Drev, Tat-Env-Env,
p17tev, and Ref comprise (parts of) Tat1, Env, Rev2, and/or Nef that are fused together in frame. In case of Tat∧8c, a few amino acids encoded by the nef/LTR overlap
(that are not in frame with the nef ORF) are fused to the C-terminus of Tat1.
chimeric Rev1-Tat2 or Tat1-Rev2 proteins (Figure 2, Table 1)
(Schwartz et al., 1990a; Purcell and Martin, 1993; Ocwieja et al.,
2012; Vega et al., 2016). Although at least some of these splice
sites can be found in diverse subtypes of (primary) HIV-1 group
M isolates (Vega et al., 2016), the expression of chimeric Tat/Rev
proteins and their possible role in viral replication has never been
investigated.
Tat1-Env and Rev1-Env Chimeras
Alternative splicing at the Rev1-Rev2/Tat1-Tat2 junctionmay not
only result in the production of Tat-Rev chimeras, but also entail
the expression of unusual Rev-Env or Tat-Env fusion proteins
(Figure 2, Table 1). For example, usage of acceptors A7g and h
in conjunction with donor D4 results in a +2 frameshift that
enables the expression of a Tat1-Env protein (Vega et al., 2016).
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Conversely, splicing at A7e induces a +1 frameshift and the
resulting RNA species have the potential to express a Rev1-Env
fusion protein (Ocwieja et al., 2012). Due to preferential usage
of acceptor A5, however, the majority of mRNA species using
alternative splice sites of A7 may lack the rev1 and tat1 initiation
codons and express Nef instead (Ocwieja et al., 2012; Vega et al.,
2016).
p186Drev/p19/p20
Depending on the specific splice acceptor used, the cryptic env
exon 6D can be fused to different exons at its 5′ end. Notably, a
TNV/p28tev fusion protein can only be synthesized upon usage
of splice acceptor 3 (A3) since alternative utilization of A4 and
A5 results in a loss of the tat1 initiation codon (Figure 2). In
the latter case, two methionine residues in exon 6D may serve
as alternative start codons and result in the expression of a
6D/Env-Rev2 fusion protein (Göttlinger et al., 1992; Neumann
et al., 1994). Experiments in transfected HeLa and COS-7 cells
as well as chronically infected H9 and CEM cells revealed that at
least the HIV-1 M HXB2 clone and HIV-1 pm213 L1, a closely
related strain, are able to express this fusion protein. According
to its apparent size in the gel, this unusual viral protein has
been termed p186Drev (Benko et al., 1990; Schwartz et al., 1990a;
Wentz et al., 1997), p19 (Göttlinger et al., 1992), or p20 (Salfeld
et al., 1990). In contrast to TNV/p28tev, which is exclusively
localized in nucleoli, p186Drev can be found in both nucleoli and
the cytoplasm (Benko et al., 1990). Thus, the Env domain seems
to affect the otherwise nuclear localization of Rev2. Furthermore,
p186Drev did not display any significant Rev activity (Benko et al.,
1990). This is in agreement with the finding that both the N- and
C-terminal parts of Rev are required for nuclear targeting and
functional activity of this regulatory protein (Malim et al., 1989).
Tat-Env-Env
Analyzing the HIV-1 clone 89.6, Ocwieja and colleagues
identified another cryptic splice acceptor site (named A6a) that
lies 52 bp downstream of A6 (Ocwieja et al., 2012). RNAs
generated via splicing at this site are predicted to encode a
tripartite Tat-Env-Env fusion protein comprising the N-terminus
of Tat and two stretches (aa 145–169 and 716–853) of Env
(Figure 2, Table 1). Similar to A6, however, acceptor A6a is not
well conserved among different strains of HIV-1. This is also
true for splice donor D5, which is required for the generation
of both, TNV/p28tev and Tat-Env-Env encoding RNA (Ocwieja
et al., 2012).
p17tev
In 1991, Furtado and colleagues identified a novel splice acceptor
site (SA8671) in env, located 240 bases downstream of the
canonical tat/rev splice acceptor A7 (Figure 2). As a result,
the tat1 encoding exon may be fused in frame to an exon
encoding the C-terminal 58 amino acids of Env gp41 (Furtado
et al., 1991). Experiments in transfected COS cells and rabbit
reticulocyte extracts demonstrated that the respective mRNA
indeed expressed a 17 kDa protein (named p17tev) that can
be detected by both Tat- and gp41-specific antibodies. RNase
protection experiments, however, showed that p17tev encoding
mRNA is only expressed at very low levels, which may explain
why the authors failed to detect this fusion protein in infected H9
cells or primary lymphocytes. Reporter assays revealed that p17tev
exerts only weak transactivating activity although it comprises
the whole N-terminus of Tat, encoded by tat1. Unlike other
mutated Tat proteins (Pearson et al., 1990), p17tev did not exert
any dominant negative effect on wild type Tat (Furtado et al.,
1991).
Tat∧8c/Tat1.4.8b
In contrast to splice acceptors A6 and SA8671, which have only
been detected in few lab-adapted clones of HIV-1, several groups
reported the presence of additional splice acceptor sites (A8a–
e) in the nef genes of both laboratory-adapted and primary
isolates of HIV-1 (Smith et al., 1992; Carrera et al., 2010; Ocwieja
et al., 2012) (Figure 2). These sites result in the generation of a
previously unappreciated class of 1 kb transcripts. Intriguingly,
A8c may be used as frequently as acceptor A7, which is required
for expression of regular Rev and Tat proteins (Ocwieja et al.,
2012). Splice events joining donor D5 to acceptors A8a–e result
in mRNA species that have the potential to encode Tat1-Nef
fusion proteins. For example, Carrera and colleagues predicted
the expression of a Tat1.4.8b protein upon splicing of D4 to A8b.
This fusion protein consists of the N-terminus of Tat and 18
amino acids encoded by the nef /LTR region (Carrera et al.,
2010). Notably, however, the 18 C-terminal amino acids do not
contain any functional motifs of Nef, as tat1.4.8b and nef are not
translated in the same reading frame. More recently, Ocwieja and
colleagues identified mRNA species in infected primary CD4+
T cells, which resulted from splicing of D4 to A8c (Ocwieja
et al., 2012). These mRNAs express a Tat∧8c fusion protein
consisting of Tat1 and 25 novel amino acids encoded by the
nef /LTR locus. In transfected TZM-bl cells, this protein exerted
only weak transactivating activity. Notably, analyses of PBMCs
from HIV-1 infected individuals demonstrated that acceptors A8
may also be fused to donor D1, resulting in RNA species that
have the potential to encode a truncated protein, consisting of
the C-terminal 34 amino acids of Nef (Smith et al., 1992; Carrera
et al., 2010). Although the initiation codon of this protein, named
C-Nef-34, is conserved among most clades of HIV-1 group M
(Carrera et al., 2010) and although the majority of HIV-1 and
HIV-2 strains contain at least one A8 site (Ocwieja et al., 2012),
the importance of C-Nef-34 and/or Tat∧8c for viral replication
has remained unclear.
Ref
Tat∧8c/Tat1.4.8b is not the only fusion protein containing amino
acid sequences encoded by the nef /LTR locus of HIV-1. cDNA
sequence analyses of cells infected with HIV-1 M 89.6 revealed
the expression of mRNA species, in which an rev1 encoding
exon is joined to an exon containing the 3′ part of the nef
ORF (Figure 2) (Ocwieja et al., 2012). These transcripts are the
result of splicing events involving acceptors A4a–c and A8c, and
encode a fusion of Rev1 and the C-terminal 80 amino acids
of Nef. In reference to its parental proteins Rev and Nef, this
fusion protein was named Ref. Although the amount of Ref
encoding transcripts exceeded 20% of all completely spliced 1 kb
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mRNA species, a fusion protein was hardly detectable. A 12.5 kDa
protein representing Ref became only detectable in transfected
HEK293T cells treated with the proteasome inhibitor MG132.
These findings suggest that the fusion protein is very unstable and
are in agreement with the observation that Ref neither exerts Rev
activity nor interferes with regular Rev function or HIV-1 particle
production (Ocwieja et al., 2012).
EXPRESSION OF A Tat-T FUSION
PROTEIN (Vpt) UPON RIBOSOMAL
FRAMESHIFTING
In addition to alternative splicing, ribosomal frameshifting
represents another mechanism that may result in the expression
of fusion proteins. The most prominent example in HIV-1 and
related primate lentiviruses is the Gag/Pol polyprotein, which is
the result of a −1 frameshift event in the gag ORF (Figure 3).
The frameshift in pol depends on a stem-loop structure stalling
the translocating ribosome and an upstream heptameric “slippery
site” where ribosomal frameshifting occurs (Dinman et al., 2002).
While the slippage heptamer (5′-UUUUUUA-3′) itself results
in frameshifting, its frequency is increased to about 5% by the
adjacent stem-loop structure (Kobayashi et al., 2010; Mouzakis
et al., 2013). Interestingly, a similar combination of slippage
sequence and RNA secondary structure can be found within the
first exon of tat (Cohen et al., 1990). This second sequence (5′-
UAAAAAG-3′) is highly conserved among HIV-1 strains (Steffy
and Wong-Staal, 1991) and has been shown to result in the
expression of a cryptic reading frame called T that overlaps
with rev1 and vpu (Figure 3) (Sonigo et al., 1985; Cohen et al.,
1990). Due to a −1 frameshift, this T open reading frame (which
does not harbor an initiation codon) is fused to the N-terminus
of Tat1, resulting in the expression of a 17 kDa protein called
Tat-T or Vpt. Although the frameshift signal is evolutionarily
conserved, expression of this fusion protein in primary HIV-1
target cells is questionable. So far, this protein has only been
detected upon in vitro translation using reticulocyte extract
(Cohen et al., 1990). In fact, expression in infected T cells may
be prevented by several splice sites disrupting the T open reading
frame. In agreement with this, Tat-T/Vpt was not detectable in
Jurkat and COS cells transfected with proviral HXBc2 DNA, and
50 different patient sera failed to detect expression of this fusion
protein from an expression plasmid (Cohen et al., 1990). Finally,
Tat-T does not exert any detectable Tat or Rev activity (Cohen
et al., 1990). Nevertheless, even if Tat-T/Vpt is not expressed in
vivo, it remains to be determined whether or how the frameshift
sequence in tat1 affects translation of regular Tat.
GENE REARRANGEMENTS ENABLE THE
EXPRESSION OF A Rev1-Vpu FUSION
PROTEIN
In the majority of HIV-1 strains, the rev1 and vpu genes lie in
different reading frames and/or are separated by an intervening
stop codon (Figure 4). However, about 3% of clade A and 20% of
clade C viruses as well as some circulating recombinants thereof
encode an unusual rev1-vpu fusion gene (Kraus et al., 2010).
Analysis of primary HIV-1 isolates harboring this ORF revealed
that infected PBMCs express a Rev1-Vpu fusion protein of about
14 kDa (Langer et al., 2015). Although prevalence rates may be
skewed by sampling biases, it is tempting to speculate that more
than 10% of all circulating HIV-1 strains encode this unusual
fusion protein, as subtype C viruses are responsible for about
50% of all infections worldwide (Osmanov et al., 2002; Hemelaar
et al., 2006, 2011). Cells infected with rev1-vpu containing viruses,
however, still express regular Vpu at much higher levels than
Rev1-Vpu as most vpu encoding transcripts lack the initiation
codon of rev1 (Kraus et al., 2010; Ocwieja et al., 2012; Langer
et al., 2015): in about 75-90% of all vpu/env mRNAs, an intron
containing the start codon of Rev1 has been removed due to the
usage of splice acceptor A5 (Purcell and Martin, 1993; Ocwieja
et al., 2012). Only in 10–25% of the cases, A4 splice acceptors
are used and the complete rev1 ORF is retained. The expression
of Rev1-Vpu may be further lowered by leaky scanning, in
which the Rev1 initiation codon is skipped due to a weak Kozak
sequence.
The characterization of virus pairs differing solely in their
ability to express Rev1-Vpu revealed that the presence of this
unusual fusion gene does not affect Rev-dependent nuclear
export of incompletely spliced viral mRNAs. In agreement with
the low Rev1-Vpu:Vpu ratio, downmodulation of CD4, tetherin
counteraction and inhibition of NF-κB activation by Vpu were
not affected either (Langer et al., 2015). Since the presence
of rev1-vpu did not enhance viral replication in PBMCs or
ex vivo infected tonsillar tissue, this gene arrangement does
not seem to confer a selection advantage to HIV-1 per-se.
Interestingly, however, mutations in the rev1-vpu intervening
region strongly affected Env expression in some viruses (Langer
et al., 2015), and the presence of the fusion gene in rev/vpu/env
expression cassettes impeded pseudotyping of env-deficient
viruses (Kraus et al., 2010). Previous studies demonstrated
that HIV-1 optimizes Env expression throughout the course
of infection to increase viral infectivity and transmission while
minimizing antibody neutralization and immune activation
(Parrish et al., 2013; Krapp et al., 2016). Thus, the expression
of Rev1-Vpu may be merely an epiphenomenon of adaptive
changes modulating Env expression. This hypothesis is in
agreement with the description of several regulatory elements in
the rev1/vpu region that may modulate leaky scanning and/or
induce ribosomal shunting (Schwartz et al., 1990b; Anderson
et al., 2007; Krummheuer et al., 2007). Together with the
observation that the proportion of rev1-vpu encoding viruses
does not seem to increase over time (unpublished data), these
findings strongly suggest that the fusion gene itself has a neutral
phenotype.
SUMMARY AND CONCLUDING REMARKS
The generation of fusion proteins represents a mechanism
of increasing the coding potential of viral genomes and has
been identified in diverse viruses including primate lentiviruses,
foamy, and papilloma viruses (Lambert et al., 1989; Viglianti
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FIGURE 3 | Generation of Gag-Pol and Tat-T/Vpt by ribosomal frameshifting. Unspliced viral mRNA contains a slippery sequence and a downstream RNA
secondary structure in gag resulting in a frameshift event in about 5% of all translation events. This ribosomal frameshift signal (highlighted by an asterisk) enables the
synthesis of the Gag/Pol polyprotein instead of Gag only. A similar frameshift signal in Tat1-encoding mRNA species has been suggested to result in the expression of
an unusual protein, in which the N-terminus of Tat1 is fused to the T open reading frame (yellow) encoded by the tat1/rev1/vpu locus.
et al., 1990; Lindemann and Rethwilm, 1998). By literally piecing
together functional domains of different proteins, viruses may
generate fusion products that retain or regulate the activity
of their parental proteins and/or even exert entirely novel
functions. Although HIV-1 is among the best characterized
viruses, relatively little is known about its “fuseome,” i.e., the
entity of all viral fusion genes and proteins. To date, more
than a dozen non-canonical lentiviral fusion proteins have been
described (Table 1). While two of them, Tat-T/Vpt and Rev1-
Vpu, are the result of ribosomal frameshifting and genetic
rearrangements, respectively, the remaining ones are expressed
due to alternative splicing events. Although for some of them,
expression has been confirmed on both mRNA and protein
levels, a relevant role for all of these fusion proteins in lentiviral
replication remains questionable for several reasons: (1) Most
of the fusion proteins were only identified in a few laboratory-
adapted viruses. For example, cryptic exon 6D, which is required
for the generation of TNV/p28tev and p186Drev, has only been
described for HIV-1 HXB2 and a few closely related viruses
(Feinberg et al., 1986; Wright et al., 1986; Benko et al., 1990;
Salfeld et al., 1990; Schwartz et al., 1990a; Göttlinger et al., 1992;
Neumann et al., 1994; Wentz et al., 1997). Follow-up studies
including in vivo transcriptome analyses of patient-derived cells
failed to detect 6D transcripts in otherHIV-1 strains and subtypes
suggesting that they might represent an artifact of laboratory-
adapted viruses (Furtado et al., 1991; Smith et al., 1992; Purcell
and Martin, 1993; Vega et al., 2016). To our knowledge, Rev1-
Vpu is the only unusual fusion protein known to be expressed
by intact primary isolates of HIV-1 (Langer et al., 2015). (2)
The total cellular levels of many fusion proteins are very low.
P17tev and Tat-T/Vpt, for example, were detectable upon in
vitro translation, but not in transfected or infected T cells
(Cohen et al., 1990; Furtado et al., 1991). Similarly, Ref was not
detectable by Western blotting unless the cells were treated with
a proteasome inhibitor (Ocwieja et al., 2012). (3) Although some
fusion proteins were shown to exert the activity of their parental
proteins, several mutational analyses argue against a crucial
role of known fusion proteins in viral replication. Mutation of
the splice sites generating exon 6D, for example, revealed that
TNV/p28tev is not required for efficient replication of HIV-1
Frontiers in Microbiology | www.frontiersin.org 8 January 2017 | Volume 7 | Article 2152
Langer and Sauter Unusual HIV-1 Fusion Proteins
FIGURE 4 | Expression of a rev1-vpu fusion gene by certain HIV-1 strains. In some HIV-1 M clade A and C strains, rev1 and vpu are located in the same reading
frame and not separated by an intervening stop codon. This unusual gene arrangement results in the expression of a Rev1-Vpu fusion protein from vpu/env encoding
mRNA species. However, as the majority of vpu/env encoding mRNAs lack the rev1 initiation codon, regular Vpu is expressed at much higher levels than Rev1-Vpu.
in CD4+ T cells (Göttlinger et al., 1992). In fact, elevated
usage of exon 6D may even be detrimental for viral replication
(Wentz et al., 1997). Similarly, the majority of primary HIV-1
isolates seems to do well without a rev1-vpu fusion gene, and
gain-of-function mutations did not enhance viral replication in
PBMCs or lymphoid tissue (Kraus et al., 2010; Langer et al.,
2015).
The observation that fusion proteins are expressed only by
a fraction of HIV-1 strains and may be dispensable for viral
replication in vivo strongly suggests that their expression is
just a tolerated epiphenomenon of other adaptive changes. In
line with this hypothesis, several studies suggested that cryptic
splice sites such as A6 may have evolved to stabilize adjacent
suboptimal splice sites and/or increase mRNA stability to balance
the ratio of spliced and unspliced HIV-1 transcripts (Lu et al.,
1990; Haseltine and Wong-Staal, 1991; Göttlinger et al., 1992;
Lützelberger et al., 2006). Furthermore, novel splice sites may
also be an (inevitable) result of adaptive changes in regulatory
RNA elements, such as shunting structures or Kozak sequences.
Mutations generating a rev1-vpu fusion gene, for example, have
been shown to drastically affect env expression (Langer et al.,
2015). Finally, fusion proteins may evolve to compensate for
detrimental mutations elsewhere in the genome. One striking
example has been described by the Berkhout lab, where a Tat-
Rev fusion protein evolved to compensate for a mutation of
the rev initiation codon (Verhoef et al., 2001). The observed
Tat-Rev fusion comprised all domains of Rev and allowed the
virus to replicate almost as efficiently as the respective wild type
control.
No matter whether HIV-1 fusion proteins represent beneficial
helpers, neutral factors or even detrimental byproducts, all
of them may potentially be immunogenic and serve as T
cell epitopes and/or antibody binding sites. To better assess
their relevance for viral replication and immune activation,
it is therefore crucial to investigate viral mRNA and protein
expression in a broad and unbiased manner. Since viral gene
expression seems to depend on the cell type and the viral
strain (Ocwieja et al., 2012; Vega et al., 2016) rather than the
time point of infection (Saltarelli et al., 1996), it is especially
important to perform analyses in primary target cells infected
with diverse groups and clades of HIV-1. For example, the recent
pyrosequencing of CD4+ CD25+ lymphocytes from individuals
infected with non-B subtypes revealed that the diversity of splice
site usage and the expression of non-canonical transcripts is
substantially higher than previously anticipated (Vega et al.,
2016). Furthermore, Ocwieja and colleagues hypothesized that
cryptic splice donor sites near the 3′ end of the viral RNA such
as SD8955 or D6 may also be joined with adjacent exons of the
host and result in the expression of chimeric viral-host proteins
as previously described for self-inactivating (SIN) retroviral
vectors (Almarza et al., 2011; Ocwieja et al., 2012). Remarkably,
even defective proviruses that fail to produce infectious viral
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particles have recently been shown to express RNA species with
unusual exon combinations (Imamichi et al., 2016). Due to
large (intron) deletions, these unspliced RNAs may be exported
from the nucleus in a Rev/RRE-independent manner, where
they are predicted to produce truncated and/or chimeric viral
proteins.
Thus, it is very likely that the lentiviral fuseome will further
increase, and future analyses will reveal whether some HIV-1
strains express non-canonical fusion proteins with relevant
functions in vivo.
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